Last reviewed · How we verify
VIR-2218
At a glance
| Generic name | VIR-2218 |
|---|---|
| Also known as | Elebsiran, elebsiran |
| Sponsor | Brii Biosciences Limited |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B (PHASE2)
- A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide (PHASE3)
- A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection (PHASE1, PHASE2)
- A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection (PHASE2)
- A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection (PHASE3)
- Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection (PHASE2)
- SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection. (PHASE2)
- Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VIR-2218 CI brief — competitive landscape report
- VIR-2218 updates RSS · CI watch RSS
- Brii Biosciences Limited portfolio CI